Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Tolerability of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT07923591 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Tolerability of Treprostinil Administered Via a Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Lead sponsor
United Therapeutics
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
May 31, 2028
Enrollment
40 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with chronic obstructive pulmonary disease

Arms

As registered; 2 arms.

  • treprostinil SMI Experimentaltreprostinil SMI (treprostinil inhalation spray)

    Inhaled treprostinil administered via a SMI at concentrations of 1.34, 2.68, 4.02, and 5.36 mg/mL

  • placebo Placebo comparatorPlacebo (placebo inhalation spray)

    Inhaled placebo administered via a SMI

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Incidence of serious adverse events, severe adverse events, cardiopulmonary hospitalizations, and deaths 16 weeks

    Number and type of serious adverse events, severe adverse events, cardiopulmonary hospitalizations, and deaths observed in participants during and after use of inhaled treprostinil and placebo.

Lead sponsor's other trials

United Therapeutics, most recent start first.

Similar trials

Same condition (Hypertension, Pulmonary) and phase, most recent start first.